Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 6, 2010, Pages 591-597

  Sloane, Peter A ^a,b   Rowe, Steven M ^a,b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cystic fibrosis; cystic fibrosis transmembrane conductance regulator; new therapies

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; AMINOGLYCOSIDE DERIVATIVE; ATALUREN; FLAVONOID; GENISTEIN; GENTAMICIN; GLAFANINE; HISTONE DEACETYLASE INHIBITOR; ION CHANNEL; PHOSPHODIESTERASE INHIBITOR; QUERCETIN; SILDENAFIL; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VORINOSTAT; VRT 532; VX 770; VX 809;

CELL STRESS; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFECT; DRUG EFFICACY; GENE DELETION; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PROTEIN FOLDING; PROTEIN TRANSPORT; REVIEW;

CODON; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE THERAPY; HUMANS; MUTATION; PROTEIN FOLDING;

EID: 77958151782     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32833f1d00     Document Type: Review

References (77)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992-2001. (Pubitemid 40638370)
2. Cystic Fibrosis Foundation National Patient Registry Annual Data Report 2009. Bethesda (MD): Cystic Fibrosis Foundation; 2009.
3. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073-1080. (Pubitemid 19231815)
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-1073. (Pubitemid 19231814)
5. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059-1065. (Pubitemid 19231813)
6. Mogayzel PJ Jr, Flume PA. Update in cystic fibrosis. Am J Respir Crit Care Med 2010; 181:539-544.
7. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373:1891-1904.
8. Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol 1996; 22:387-395. (Pubitemid 27024442)
9. Loo TW, Bartlett MC, Clarke DM. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule. Biochemistry 2009; 48:9882-9890.
10. Serohijos AW, Hegedus T, Aleksandrov AA, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A 2008; 105:3256-3261. (Pubitemid 351723540)
11. Bronsveld I, Mekus F, Bijman J, et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 2001; 108:1705-1715. (Pubitemid 33144880)
12. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995; 29:777-807. (Pubitemid 26005359)
13. Haardt M, Benharouga M, Lechardeur D, et al. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis: a novel class of mutation. J Biol Chem 1999; 274:21873-21877. (Pubitemid 129519738)
14. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73:1251-1254. (Pubitemid 23201140)
15. Weinreich F, Wood PG, Riordan JR, Nagel G. Direct action of genistein on CFTR. Pflugers Arch 1997; 434:484-491. (Pubitemid 27292574)
16. Pyle LC, Fulton JC, Sloane PA, et al. Activation of CFTR by the flavonoid quercetin: potential use as a biomarker of DF508 CFTR rescue. Am J Respir Cell Mol Biol 2009. [Epub ahead of print]
17. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290:L1117-L1130. (Pubitemid 43830856)
18. Ma T, Vetrivel L, Yang H, et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 2002; 277:37235-37241.
19. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003; 278:35079-35085. (Pubitemid 37102270)
20. Thakerar A, Van Driessch A, Bridges RJ. The conductance assay: a simple assay to measure DF508-CFTR channel activity. Ped Pulmonl Suppl 2009; 32:Abstract 267.
21. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009; 106:18825-18830.
22. Galietta LJ. Problems and opportunities in mutant CFTR rescue. Pediatric Pulmonol Suppl 2009; 32: Symposium 9.1.
23. Pasyk S, Li C, Ramjeesingh M, Bear CE. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease. Biochem J 2009; 418:185-190.
24. Accurso F, Rowe SM, Durie P, et al. Interim results of a phase IIa study of VX-770 to evalaute safety, pharmacokinetics and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatr Pulmonol 2008; 43:Abstract 295.
25. Clancy JP, Rowe SM, Durie PR, et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Ped Pulmonol Suppl 2009; 32: Abstract 222.
26. Boyle M, Clancy JP, Rowe SM, et al. Effect of VX-770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D-CFTR mutation. Ped Pulmonol Supp 2009; 32: Abstract 217.
27. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100:2457-2465.
28. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157:484-490.
29. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115:2564-2571. (Pubitemid 41266219)
30. Pedemonte N, Tomati V, Sondo E,Galietta LJ. Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 2010; 298:C866-C874.
31. Varga K, Goldstein RF, Jurkuvenaite A, et al. Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 2008; 410:555-564. (Pubitemid 351429026)
32. Young A, Gentzsch M, Abban CY, et al. Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane. Biochem J 2009; 421:377-385.
33. Kim Chiaw P, Wellhauser L, Huan LJ, et al. A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 2010; 78:411-418.
34. Wellhauser L, Kim Chiaw P, Pasyk S, et al. A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol 2009; 75:1430-1438.
35. Press release, Vertex Pharmaceuticals, Inc. http://investors.vrtx.com/ releasedetail. cfm?releaseid=442429. [Accessed 2 August 2010]
36. Van Goor F, Haditha S, Grootenhuis PD, et al. VX-809, a CFTR corrector, increases the cell surface density of functional F508del-CFTR in preclinical models of cystic fibrosis. Ped Pulmonol Supp 2009; 32:Abstract 154.
37. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008; 73:478-489. (Pubitemid 351159218)
38. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177:506-515. (Pubitemid 351442189)
39. Lubamba B, Lebacq J, Reychler G, et al. Inhaled PDE5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J 2010. [Epub ahead of print]
40. Robert R, Carlile GW, Liao J, et al. Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 2010; 77:922-930.
41. Amaral MD. High-content fluorescence microscopy siRNA screens to track function/traffic of ENaC & CFTR. European CF Society: new frontiers in basic science of cystic fibrosis 2010:symposium 9.2.
42. Wiech NL, Fisher JF, Helquist P, Wiest O. Inhibition of histone deacetylases: a pharmacological approach to the treatment of noncancer disorders. Curr Top Med Chem 2009; 9:257-271.
43. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010; 6:25-33.
44. Mu TW, Ong DS, Wang YJ, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008; 134:769-781.
45. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 2007; 64:1841-1852. (Pubitemid 47096588)
46. Keeling KM, Brooks DA, Hopwood JJ, et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-Liduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001; 10:291-299.
47. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2:467-469. (Pubitemid 26191920)
48. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3:1280-1284. (Pubitemid 27508832)
49. Tok JB, Bi L. Aminoglycoside and its derivatives as ligands to target the ribosome. Curr Top Med Chem 2003; 3:1001-1019.
50. Bonetti B, Fu L, Moon J, Bedwell DM. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol 1995; 251:334-345.
51. Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104:375-381. (Pubitemid 29534321)
52. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000; 6:1044-1055. (Pubitemid 30471140)
53. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007; 5:5. (Pubitemid 46605672)
54. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:1683-1692. (Pubitemid 32578776)
55. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349:1433-1441. (Pubitemid 37211058)
56. Wilschanski M, Famini C, Blau H, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000; 161 (3 Pt 1):860-865. (Pubitemid 30171743)
57. Sermet-Gaudelus I, De Boeck K, Casimir GJ, et al. Ataluren (PTC124) Induces CFTR Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. Am J Respir Crit Care Med 2010. [Epub ahead of print]
58. Helip-Wooley A, Park MA, Lemons RM, Thoene JG. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol Genet Metab 2002; 75:128-133. (Pubitemid 34971605)
59. Sleat DE, Sohar I, Gin RM, Lobel P. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol 2001; 5 (Suppl A:):57-62. (Pubitemid 32677113)
60. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002; 80:367-376.
61. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001; 49:706-711. (Pubitemid 32530236)
62. Du M, Jones JR, Lanier J, et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/-mouse carrying a human CFTR-G542X transgene. J Mol Med 2002; 80:595-604.
63. Du M, Keeling KM, Fan L, et al. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med 2006; 84:573-582. (Pubitemid 43992849)
64. Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006; 174:787-794. (Pubitemid 44511660)
65. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009; 52:2836-2845.
66. Rowe SM, Backer K, Tang L, et al. Enhanced activity for translational readthrough and reduced toxicity demonstrated by the synthetic aminoglycoside NB54. Ped Pulmonol Supp 2009; 32:Abstract 218.
67. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447:87-91. (Pubitemid 46685839)
68. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47:430-444. (Pubitemid 46465953)
69. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 2008; 105:2064-2069. (Pubitemid 351439465)
70. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372:719-727.
71. Clancy JP, Konstan MW, Rowe SM, et al. A phase II study of PTC124 in CF patients harboring premature stop mutations. Ped Pulmonol Suppl 2006; 41:Abstract 269.
72. SolomonGM, Konstan MW, WilschanskiM, et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest 2010. [Epub ahead of print]
73. Rowe SM, Varga K, Rab A, et al. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol 2007; 37:347-356. (Pubitemid 350067614)
74. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117:683-692. (Pubitemid 46348526)
75. Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A 2009; 106:3585-3590.
76. Auld DS, Lovell S, Thorne N, et al. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci U S A 2010; 107:4878-4883.
77. Wilschanski M, Armoni S, Yaacov Y, et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. J Cyst Fibros 2008; 7:Symposium 22